30 research outputs found
ZMYND10 Is Mutated in Primary Ciliary Dyskinesia and Interacts with LRRC6
Defects of motile cilia cause primary ciliary dyskinesia (PCD), characterized by recurrent respiratory infections and male infertility. Using whole-exome resequencing and high-throughput mutation analysis, we identified recessive biallelic mutations in ZMYND10 in 14 families and mutations in the recently identified LRRC6 in 13 families. We show that ZMYND10 and LRRC6 interact and that certain ZMYND10 and LRRC6 mutations abrogate the interaction between the LRRC6 CS domain and the ZMYND10 C-terminal domain. Additionally, ZMYND10 and LRRC6 colocalize with the centriole markers SAS6 and PCM1. Mutations in ZMYND10 result in the absence of the axonemal protein components DNAH5 and DNALI1 from respiratory cilia. Animal models support the association between ZMYND10 and human PCD, given that zmynd10 knockdown in zebrafish caused ciliary paralysis leading to cystic kidneys and otolith defects and that knockdown in Xenopus interfered with ciliogenesis. Our findings suggest that a cytoplasmic protein complex containing ZMYND10 and LRRC6 is necessary for motile ciliary function
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049
The Concise guide to pharmacology 2019/20: Ion channels
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, pointâinâtime record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14749. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G proteinâcoupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to midâ2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NCâIUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, pointâinâtime record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15539. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G proteinâcoupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to midâ2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NCâIUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate
The Concise Guide to PHARMACOLOGY 2023/24: Ion channels
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, pointâinâtime record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16178. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G proteinâcoupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to midâ2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NCâIUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate
Rare copy number variation in posttraumatic stress disorder
Posttraumatic stress disorder (PTSD) is a heritable (h2â=â24-71%) psychiatric illness. Copy number variation (CNV) is a form of rare genetic variation that has been implicated in the etiology of psychiatric disorders, but no large-scale investigation of CNV in PTSD has been performed. We present an association study of CNV burden and PTSD symptoms in a sample of 114,383 participants (13,036 cases and 101,347 controls) of European ancestry. CNVs were called using two calling algorithms and intersected to a consensus set. Quality control was performed to remove strong outlier samples. CNVs were examined for association with PTSD within each cohort using linear or logistic regression analysis adjusted for population structure and CNV quality metrics, then inverse variance weighted meta-analyzed across cohorts. We examined the genome-wide total span of CNVs, enrichment of CNVs within specified gene-sets, and CNVs overlapping individual genes and implicated neurodevelopmental regions. The total distance covered by deletions crossing over known neurodevelopmental CNV regions was significant (betaâ=â0.029, SEâ=â0.005, Pâ=â6.3âĂâ10-8). The genome-wide neurodevelopmental CNV burden identified explains 0.034% of the variation in PTSD symptoms. The 15q11.2 BP1-BP2 microdeletion region was significantly associated with PTSD (betaâ=â0.0206, SEâ=â0.0056, Pâ=â0.0002). No individual significant genes interrupted by CNV were identified. 22 gene pathways related to the function of the nervous system and brain were significant in pathway analysis (FDR qâ<â0.05), but these associations were not significant once NDD regions were removed. A larger sample size, better detection methods, and annotated resources of CNV are needed to explore this relationship further
Habituation of the Visually Evoked Potential and Its Vascular Response: Implications for Neurovascular Coupling in the Healthy Adult
GesamtdissertationModerne nicht-invasiv bildgebende Verfahren des Gehirns basieren auf dem
Prinzip der neurovaskulÀren Kopplung, dem PhÀnomen, dass aktivierte Hirnareale
aufgrund eines erhöhten Energieverbrauches stÀrker durchblutet werden. Wie die
Ăbersetzung neuronaler AktivitĂ€t in die resultierende vaskulĂ€re Antwort
erfolgt, ist bislang nur unvollstÀndig verstanden. Unter lang anhaltender
Stimulation wurde eine Amplitudenreduktion der vaskulÀren Antwort beschrieben.
Dies fĂŒhrte zu der Annahme, dass eine transiente âEntkopplung" zwischen
neuronaler AktivitÀt und vaskulÀrem Signal auftrete, die aufgrund
unterschiedlicher metabolischer Prozesse zu Beginn und im Verlauf der
Stimulation erklÀrt wurden. Bisher ist jedoch ungeklÀrt, inwieweit dies allein
auf metabolischen Umstellungen oder neuronalen und vaskulÀren
Gewöhnungseffekten an den wiederkehrenden Reiz, im Sinne einer Habituation,
beruht. In der vorliegenden Studie werden neuronale und vaskulÀre Habituation
unter visueller Stimulation (3 Hz Kontrastumkehr) simultan mittels Visuell
Evozierten Potentialen (VEP) und Nahinfrarot-Spektroskopie (NIRS) untersucht.
Habituationseffekte wurden auf zwei Zeitskalen untersucht. Innerhalb eines
einminĂŒtigen Stimulationsblockes zeigte sich eine signifikante Reduktion der
P100N135-Amplitude des VEPs in Korrelation mit einer Reduktion der vaskulÀren
Parameter (KonzentrationsÀnderungen des oxygenierten und deoxygenierten
HĂ€moglobins; [oxy-Hb] und [deoxy-Hb]). Ăber 13 sukzessive Stimulationsblöcke
zeigte sich nur ein schwacher Trend hinsichtlich einer neuronalen Habituation
ohne Relation zur vaskulÀren Antwort. Anhand der Ratio zwischen VerÀnderungen
der P100N135-Amplitude des VEPs und der KonzentrationsÀnderungen der
vaskulĂ€ren Parameter ([oxy-Hb] und [deoxy-Hb]) innerhalb des einminĂŒtigen
Stimulationsblockes konnte ein Kopplungsindex definiert werden. Es ergab sich
ein Abfall des [deoxy-Hb] um 0,02 ”M und ein Anstieg des [oxy-Hb] um 0,06 ”M
pro 1 ”V Zunahme der P100N135-Amplitude. Dieser Kopplungsindex war sowohl fĂŒr
den Stimulations- als auch den Habituationseffekt konstant. Diese Ergebnisse
unterstĂŒtzen die Vorstellung eines linearen VerhĂ€ltnisses der neurovaskulĂ€ren
Kopplung und sprechen gegen eine transiente Entkopplung neuronaler AktivitÀt
und vaskulÀrer Antwort aufgrund metabolischer Umstellungen.Non-invasive imaging methods of the brain are based on the neurovascular
coupling, the phenomenon of an increased regional blood flow of functionally
activated brain regions due to an increased energy demand. There are, however,
a number of unresolved questions, i.e. regarding the translation from the
neuronal activation to the vascular response. For prolonged stimulations a
reduction of the vascular response has been shown. This led to the assumption
of an transient uncoupling of neuronal activity and vascular signal due to a
shift from non-oxidative to oxidative metabolism. So far, it is unclear,
whether these changes could also be explained by neuronal habituation that
will be mirrored by the closely linked vascular response. In this study,
visually evoked potentials (VEP) and cerebral oxygenation changes, as measured
by near-infrared spectroscopy (NIRS), are assessed to elucidate the relation
between electrophysiological and vascular responses to a checkerboard stimulus
reversing at 3 Hz. Habituation of either response is analysed on two time
scales. Within the 1-min stimulation period a significant decrease in
P100N135-component amplitude was closely coupled to a significant decrease in
the amplitude of the oxygenation parameters (concentration changes in
oxygenated and deoxygenated haemoglobin, [oxy-Hb] and [deoxy-Hb]). The
analysis across the 13 successive stimulation blocks yields a trend for a
decrease in the VEP-components' amplitude, not reflected in the vascular
response. When calculating a ratio between the amplitude of the
P100N135-component and the concentration changes in the vascular parameters a
"coupling index" of a 0,02 ”M decrease in [deoxy-Hb] and an increase of 0,06
”M in [oxy-Hb] is found per 1 ”V increase in the P100N135-component amplitude.
The ratio is the same irrespective of its assessment from the stimulation
effect or the habituation effect. These results support the notion that the
coupling between neuronal activation and the vascular response exhibits linear
aspects and thus might argue against a transient uncoupling of neuronal
activity and vascular response due to oxidative metabolism
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
More than 20 years have passed without the launch of a new substance class for acute migraine therapy. Triptans were the latest class of substances which successfully passed all developmental stages with a significant antimigraine efficacy and a sufficient safety profile. New drugs with a better adverse event profile and at least similar efficacy are needed for migraine subjects who cannot tolerate triptans for attack treatment. Lasmiditan is a novel highly specific 5-HT 1F receptor agonist currently in clinical trials for acute migraine therapy and devoid of vasoconstriction in coronary arteries as determined in a surrogate assay. In both phase II randomized, placebo-controlled trials in acute migraine the primary endpoint was met. For the intravenous formulation a clear dose-dependent effect on headaches could be determined. Lasmiditan tablets in doses of 50â400 mg show significant headache relief after 2 hours compared with placebo and improved accompanying symptoms. This substance is chemically clearly different from other antimigraine drugs, which is also reflected by its dose-dependent adverse event profile chiefly including dizziness, vertigo, paresthesia and fatigue. Adverse events are usually linked to the central nervous system. Future phase III clinical trials with an active triptan comparator or in a preferential trial design will allow a better comparison of lasmiditan and triptans. They will also determine whether lasmiditan will become available to the migraine patient
A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model.
SKA-31, an activator of endothelial KCa2.3 and KCa3.1 channels, reduces systemic blood pressure in mice and dogs, however, its effects in larger mammals are not well known. We therefore examined the hemodynamic effects of SKA-31, along with sodium nitroprusside (SNP), in anesthetized, juvenile male domestic pigs. Experimentally, continuous measurements of left ventricular (LV), aortic and inferior vena cava (IVC) pressures, along with flows in the ascending aorta, carotid artery, left anterior descending coronary artery and renal artery, were performed during acute administration of SKA-31 (0.1, 0.3, 1.0, 3.0 and 5.0mg/ml/kg) and a single dose of SNP (5.0 Όg/ml/kg). SKA-31 dose-dependently reduced mean aortic pressure (mPAO), with the highest dose decreasing mPAO to a similar extent as SNP (-23 ± 3 and -28 ± 4 mmHg, respectively). IVC pressure did not change. Systemic conductance and conductance in coronary and carotid arteries increased in response to SKA-31 and SNP, but renal artery conductance was unaffected. There was no change in either LV stroke volume (SV) or heart rate (versus the preceding control) for any infusion. With no change in SV, drug-evoked decreases in LV stroke work (SW) were attributed to reductions in mPAO (SW vs. mPAO, r(2)=0.82, P<0.001). In summary, SKA-31 dose-dependently reduced mPAO by increasing systemic and arterial conductances. Primary reductions in mPAO by SKA-31 largely account for associated decreases in SW, implying that SKA-31 does not directly impair cardiac contractility
Pharmacological evaluation of the anxiolytic-like effects of an aqueous extract of the Raphanus sativus L. sprouts in mice
Raphanus sativus L. (Brassicaceae), commonly known as radish, is consumed worldwide as a vegetable. However, its benefits on mental health are unknown. The aim of this study was to evaluate its anxiolytic-like effects and safety using different experimental models. An aqueous extract of R. sativus sprouts (AERSS) was pharmacologically evaluated by intraperitoneal route (i.p.) at 10, 30, and 100 mg/kg and orally (p.o.) at 500 mg/kg on behavior by using open-field and plus-maze tests. In addition, its acute toxicity (LD50) was determined by the Lorke's method. Diazepam (1 mg/kg, i.p.) and buspirone (4 mg/kg, i.p.) were the reference drugs. A significant and anxiolytic-like dosage of AERSS (30 mg/kg, i.p.) resembling the effects of reference drugs was chosen to explore the involvement of GABAA/BDZs site (flumazenil, 5 mg/kg, i.p.) and serotonin 5-HT1A receptors (WAY100635, 1 mg/kg, i.p.) as a possible mechanism of action. A 500 mg/kg, p.o. dosage of AERSS produced an anxiolytic-like response equivalent to 100 mg/kg, i.p. No acute toxicity was observed since a LD50 > 2000 mg/kg, i.p. The phytochemical analysis allowed the identification and quantification of major presence of sulforaphene (2500 ”M), sulforaphane (15 ”M), iberin (0.75 ”M), and indol-3-carbinol (0.75 ”M), as major constituents. Both the GABAA/BDZs site and serotonin 5-HT1A receptors were involved in the anxiolytic-like activity of AERSS, depending on the pharmacological parameter or the experimental assay tested. Our results demonstrate that the anxiolytic activity of R. sativus sprouts involves GABAA/BDZs site and serotonin 5-HT1A receptors supporting its health benefits in the treatment of anxiety beyond the satisfaction of basic nutritional needs